Sign up Australia
Proactive Investors - Run By Investors For Investors

Genetic Technologies tops ASX Most Traded ahead of Nasdaq trading

Genetic Technologies has traded $1.7 million of stock by noon.
Genetic Technologies tops ASX Most Traded ahead of Nasdaq trading
The ASX most active

Genetic Technologies Ltd (ASX:GTG; Nasdaq:GENE) is the most active stock intra-day with over 113 million shares changing hands, although its value has eased 10.5% to $0.017.

The company has regained compliance with Nasdaq Marketplace following a deficiency notice in mid-2017.

Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health.

The company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.

Adding interest and following a strategic review, the company remains in active discussions with multiple parties regarding a potential transaction.

Further details will be closely monitored by investors.

Company Name Code Last Change Volume
Genetic Technologies Ltd GTG $0.017 -10.53% 113,744,014
Pancontinental Oil & Gas NL PCL $0.005 0% 95,747,144
Queensland Bauxite Ltd QBL $0.069 -8% 71,822,947
Bard1 Life Sciences Ltd BD1 $0.016 33.33% 64,333,658
Atlas Iron Ltd AGO $0.032 -3.03% 64,299,962
Ardiden Ltd ADV $0.023 15% 61,450,080
Serpentine Technologies Ltd S3R $0.017 21.43% 49,188,225
Fatfish Internet Group Ltd FFG $0.100 21.95% 36,935,922
Kairos Minerals Ltd KAI $0.055 14.58% 32,602,587
Lepidico Ltd LPD $0.067 6.35% 27,529,056

 

View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

1505911280_social-media.jpg
September 20 2017
The Cello Health unit led the way as it grew organically and via the acquisition of Defined Health
picture of Hunger Games cast
November 27 2017
Some of the most famous films ever made have been backed by FFI since it was founded in 1950
Laptop screen with graphs
August 04 2017
Total revenues for the six months to 30 June grew by 5%, with Ebiquity adding it remains confident in hitting its operating profits and earnings targets for the rest of the year

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use